Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
Ardelyx, Inc. reported higher Q1 2026 revenue but remains unprofitable as it invests heavily in commercialization and pipeline growth. Total revenues reached $94.5 million, up from $74.1 million, driven mainly by product sales.
Net product sales were $93.4 million, led by IBSRELA at $70.1 million (up 58%) and XPHOZAH at $23.3 million, roughly flat year over year. The company recorded a net loss of $37.6 million, slightly improved from $41.1 million, as operating expenses grew to support marketing and R&D. Ardelyx ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and $203.5 million of long-term debt, and later refinanced its loan facility to extend maturities and lower interest rates.
Ardelyx reported strong first quarter 2026 growth while remaining loss-making. Total product revenue reached $93.4 million for the quarter ended March 31, 2026, up 38% from $67.8 million a year earlier, driven mainly by IBSRELA sales of $70.1 million, which grew 58% year-over-year.
XPHOZAH contributed $23.3 million in revenue, and total revenue including other items was $94.5 million. Operating expenses rose as Ardelyx invested in commercialization and R&D, leading to a net loss of $37.6 million, or $(0.15) per share, slightly improved from a $41.1 million loss a year earlier. The company ended the quarter with $238.1 million in cash, cash equivalents and short-term investments and reiterated 2026 revenue guidance of $410–$430 million for IBSRELA and $110–$120 million for XPHOZAH, while advancing its pipeline, including the Phase 3 ACCEL trial in chronic idiopathic constipation and preclinical candidate RDX10531.
Ardelyx, Inc. is asking stockholders to vote at its fully virtual 2026 Annual Meeting on June 16, 2026 at 8:30 a.m. Eastern Time. Holders of common stock as of April 22, 2026 can vote online, by phone, mail, or during the live webcast.
Stockholders will vote on electing three Class III directors, an advisory Say‑on‑Pay resolution, how often to hold future Say‑on‑Pay votes, ratification of Ernst & Young LLP as auditor for 2026, and an amendment to the 2014 Equity Incentive Award Plan to add 9,000,000 shares. Ardelyx highlights strong governance practices, including an independent chair, fully independent board committees, a classified board structure, and extensive pay‑for‑performance features and clawback, ownership, and anti‑hedging policies.
Ardelyx, Inc. Schedule 13G/A discloses passive institutional holdings by Millennium-related entities and Integrated Core Strategies. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report 18,043,970 shares (7.4%) and Integrated Core Strategies (US) LLC reports 17,721,732 shares (7.2%). The filing is a joint filing documented by a April 24, 2026 Joint Filing Agreement.
ARDELYX, INC. filed an initial ownership report for Chief Legal Officer Felecia Ettenberg. The filing shows direct ownership of 237,000 shares of Common Stock.
It also reports a stock option to buy 355,000 shares of Common Stock at an exercise price of $6.30 per share, expiring on April 20, 2036. According to the vesting schedule, 25% of the option vests on April 20, 2027, with the remaining shares vesting in 36 equal monthly installments if her employment continues. Footnotes further note restricted stock units that convert into one share of Common Stock for each unit upon vesting.
ARDELYX, INC. President & CEO Michael Raab exercised stock options and sold shares in a planned transaction. He exercised options for 20,834 shares of common stock at an exercise price of $0.99 per share, then sold 41,668 common shares at a weighted average price of $6.2867 per share pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025. After these transactions, he holds 1,795,614 shares directly, plus additional indirect holdings of 24,364 and 1,000 shares held in family trusts.
ARDELYX, INC. Chief Medical Officer Dinavahi Rajani reported her equity holdings in connection with a Form 3 filing. She holds stock options to purchase 301,000 shares of Common Stock at an exercise price of $6.11 per share, expiring on April 1, 2036.
She also directly holds 201,000 shares of Common Stock. The option grant vests over time, with 25% of the shares vesting on April 1, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to her continued employment or service with the company.
Ardelyx Inc received an amended Schedule 13G/A from The Vanguard Group reporting that, following an internal realignment, Vanguard and its subsidiaries/ divisions will report holdings separately. The filing states amount beneficially owned: 0 and percent of class: 0% as of 03/13/2026.
The amendment cites SEC Release No. 34-39538 (January 12, 1998) and explains that certain Vanguard subsidiaries that formerly were reported under The Vanguard Group, Inc. will now report on a disaggregated basis. The signing official is Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
ARDELYX, INC. President & CEO Michael Raab exercised stock options to acquire 20,833 shares of common stock at $0.99 per share, then sold 41,666 shares at a weighted average price of $5.84 per share under a pre-arranged Rule 10b5-1 trading plan.
After these transactions, he held 1,816,448 common shares directly and 374,168 stock options of this award, plus indirect holdings of 24,364 and 1,000 shares through family trusts for his children.